The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 15, 2015
Filed:
Sep. 14, 2010
Dae-yoon Chi, Seoul, KR;
Byoung-se Lee, Seoul, KR;
Sirion Uthaiwan, Chainat, TH;
So-young Chu, Seoul, KR;
Yu-jin Bae, Incheon, KR;
Chansoo Park, Seoul, KR;
Dae-hyuk Moon, Seoul, KR;
Jin-sook Ryu, Seoul, KR;
Jae-seung Kim, Seoul, KR;
Seung-jun OH, Seoul, KR;
Dae-Yoon Chi, Seoul, KR;
Byoung-Se Lee, Seoul, KR;
Sirion Uthaiwan, Chainat, TH;
So-Young Chu, Seoul, KR;
Yu-Jin Bae, Incheon, KR;
Chansoo Park, Seoul, KR;
Dae-Hyuk Moon, Seoul, KR;
Jin-Sook Ryu, Seoul, KR;
Jae-Seung Kim, Seoul, KR;
Seung-Jun Oh, Seoul, KR;
FUTURECHEM CO., LTD., Incheon, KR;
Abstract
The present invention relates to (3-fluoro-2-hydroxy)propyl-functionalized aryl derivatives or to the pharmaceutically acceptable salt thereof, to a method for preparing same, and to a pharmaceutical composition containing same as active ingredients for the diagnosis or treatment of neurodegenerative brain diseases. The aryl derivatives of the present invention are (3-fluoro-2-hydroxy)propyl-functionalized to increase the polarity thereof, and therefore the drugs containing the aryl derivatives can easily permeate into the cerebrovascular membrane, thus increasing the effectiveness of the drugs. As the aryl derivatives of the present invention strongly bind to β-amyloid, the aryl derivatives, when labeled with radioisotope, can be used as a diagnostic agent for non-invasively diagnosing early Alzheimer's disease. Further, the aryl derivatives of the present invention bind to low molecular β-amyloid peptide conjugates to inhibit the generation of malignant high molecular β-amyloid plaque, and thus can be effectively used as a therapeutic agent for neurodegenerative brain diseases such as Alzheimer's disease.